Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab

Tumori

Volumn 96, Issue 3, 2010, Pages 473-477

  Brugger, Wolfram ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cetuximab; Colorectal cancer; Infusion reaction; Panitumumab

Indexed keywords

ANTIHISTAMINIC AGENT; BENZODIAZEPINE; BEVACIZUMAB; BRONCHODILATING AGENT; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CORTICOSTEROID; DEXAMETHASONE; DIMETINDENE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PREDNISONE; RANITIDINE;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASE REPORT; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GLOVE; HEMICOLECTOMY; HUMAN; HYPOTENSION; LOADING DRUG DOSE; LUNG METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT RESPONSE; ULTRASOUND;

EID: 77955007931     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600316     Document Type: Article

References (22)

1. Erbitux® (cetuximab) prescribing information: New York: ImClone Systems Incorporated and Princetown, NJ: Bristol-Myers Squibb Company 2008.
2. Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, Weiss KD, Pazdur R: US Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res, 14: 1296-1302, 2008.
3. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22: 1201-1208, 2004.
4. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol, 25: 3644-3648, 2007.
5. Lenz HJ: Management and preparedness for infusion and hypersensitivity reactions. Oncologist, 12: 601-609, 2007.
6. Patel DD, Goldberg RM: Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park), 20: 1373-1382, 2006.
7. Saif MW, Cohenuram M: Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer, 6: 118-124, 2006.
8. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol, 25: 1658-1664, 2007.
9. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M: An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol, 19: 92-98, 2008.
10. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R: FDA drug approval summary: panitumumab (Vectibix). Oncologist, 12: 577-583, 2007.
11. Helbling D, Borner M: Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol, 18: 963-964, 2007.
12. Heun J, Holen K: Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer, 6: 529-531, 2007.
13. Cartwright TH, Genther R: Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. Clin Colorectal Cancer, 7: 202-203, 2008.
14. Saif MW, Peccerillo J, Potter V: Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol, 63: 1017-1022, 2009.
15. Peeters M, Price T, Hotko Y, Cervantes A, Ducreux M, André T, Chan E, Lordick F, Rong A, Gansert J: Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. EJC Supplements, 7: 10 (14LBA), 2009.
16. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26: 1626-1634, 2008.
17. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol, 16: 1425-1433, 2005.
18. Lacouture ME, Melosky BL: Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett, 12: 1-5, 2007.
19. Zhang W, Gordon M, Lenz HJ: Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med, 38: 545-551, 2006.
20. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, Milanesi E, Ciorba A, Paris M, Facilissimo I, Macripo G, Clerico M, Ciuffreda L: Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer, 7: 48-54, 2008.
21. Chung CH: Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist, 13: 725-732, 2008.
22. Lenz HJ: Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park), 20 (5 Suppl 2): 5-13, 2006.